Clinical trial · Observational
Study on Clinical Features, Treatment Mode and Survival of Sarcoma
A Single-center Retrospective Study of Clinical Features, Treatment Patterns, and Survival of Sarcomas
NCT05453409CI-TRIAL-00073775unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The clinical data of all eligible patients who received chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgery in Henan Tumor Hospital from June 1, 2012 to May 30, 2022 were retrospectively collected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- Up to approximately 24months
- description
- Progression-free survival is defined as time from enrollment to the first occurrence of progression of disease or death from any cause within 63 days of last response assessment.
- measure
- Overall survival
- timeFrame
- Up to approximately 120months
- description
- Time from pathological diagnosis to death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: No age limit, male or female. A certain subtype of sarcoma was diagnosed by pathology in our hospital. Has received at least one hospitalization in this hospital. Target lesions can be evaluated according to solid tumor efficacy evaluation criteria (RECIST; Version 1.1) Measure diameter changes. Complete follow-up data. Exclusion Criteria: No clear pathology. Incomplete follow-up data.
References
Publications (0)
Data not yet available
No reference posted for this study.